2019 Enanta Pharmaceuticals Announces Topline Results Showing EDP-938 Achieved its Primary and Secondary Endpoints in a Phase 2a Human Challenge Study in Healthy Adults Infected with Respiratory Syncytial Virus Enanta Adds Hepatitis B Virus to its Pipeline with the Initiation of Phase 1 Clinical Study of Core Inhibitor EDP-514